IP Library Granted Patent US 11,110,159
Granted Patent B2
US 11,110,159 · App. 15/747,671 · Granted Sep 7, 2021

Methods for inducing an immune response

Inventors: Marie-Ange Demoitie (Rixensart, BE); Marie-Noelle Renelle Donner (Rixensart, BE); Nadia Ouaked (Rixensart, BE)
Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
A61K39/04A61K9/0019A61K35/761A61K39/12A61K39/39A61K45/05A61P31/06C07K14/005C07K14/35C12N7/00C12N15/85C12N15/86A61K2039/5256A61K2039/545C12N2710/10321C12N2710/10341C12N2710/10343C12N2740/16234C12N2760/18534
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,110,159
App. No.
15/747,671
Granted
Sep 7, 2021
Kind
B2
Abstract

The present invention relates to methods for inducing an immune response, in particular methods for inducing an immune response against mycobacterial infections or disease comprising (i) at least one administration of a polypeptide Rv1196 related antigen and at least one administration of an adenovirus encoding a Rv1196 related antigen or (ii) at least one administration of a polypeptide Rv0125 related antigen and at least one administration of an adenovirus encoding a Rv0125 related antigen. Associated compositions, adenoviral constructs and polynucleotide sequences are also provided.

Claims (10)

1. A method for inducing an immune response comprising a T cell response in a subject comprising:

administration of a chimpanzee adenovirus encoding a Rv1196 related antigen comprising SEQ ID NO: 1, followed by administration of a polypeptide Rv1196 related antigen to the subject, wherein the polypeptide Rv1196 related antigen is provided in a composition which also comprises an adjuvant.

2. The method of claim 1 wherein the adjuvant comprises a Toll Like Receptor (TLR) agonist and/or an immunologically active saponin.

3. The method of claim 1 wherein the adjuvant comprises 3-O-deacylated monophosphoryl lipid A (3D-MPL).

4. The method of claim 1 wherein the adjuvant comprises QS21.

5. The method of claim 1 wherein the chimpanzee adenovirus is a ChAd3.

6. The method of claim 1 wherein the chimpanzee adenovirus is a ChAd63.

7. The method of claim 1 , wherein the Rv1196 related antigen comprises SEQ ID NO: 6.

8. The method of claim 1 , wherein the composition in which the polypeptide Rv1196 related antigen provided is substantially free of a non-human simian adenovirus encoding the Rv1196 related antigen.

9. The method of claim 1 , wherein the composition in which the polypeptide Rv1196 related antigen provided does not comprise a non-human simian adenovirus encoding the Rv1196 related antigen.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2021
From: DEMOITIE, MARIE-ANGE; DONNER, MARIE-NOELLE; OUAKED, NADIA
To: GLAXOSMITHKLINE BIOLOGICALS SA
Reel/Frame 055558/0702 →
Priority Claims (1)
GB 1513176 · Jul 27, 2015 · national
Continuity (1)
Related Publication 20180250375A1 · Sep 6, 2018
Cited By (3)
US 12,295,997 US 12,582,683 US 12,692,513